Cart
Tyrosine Kinase/Adaptors c-Met/HGFR

c-Met/HGFR

c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor.MET is a single pass tyrosine kinase receptor essential for embryonic development, organogenesis and wound healing.
Cat No. product name
T1661 CrizotinibHOT Crizotinib is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.
T1797 XL184 Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential ...
T1918 TAE226 NVP-TAE226 is an effective FAK inhibitor (IC50: 5.5 nM) and most effective to Pyk2(IC50: 3.5 nM); 10- to 100-fold less effective against IGF-1R, InsR, c-Met, an...
T1963 Capmatinib Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
T2054 Altiratinib Altiratinib(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth...
T2282 RPI-1 RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor. 
T2293 SGX-523 SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
T2349 BMS-754807 Dual IGF-1R/InsR Inhibitor BMS-754807 is an oral small molecule inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine...
T2419 BMS794833 BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.
T2586 CabozantinibHOT Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50s: 0.035, 1.3, 4.6, 7 and 11.3 nM).
T2676 PF-04217903 MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.
T2680 NVP-BVU972 NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.
T2699 BMS-777607 BMS-777607 is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3 (IC50: 3.9/1.1/1.8/4.3 nM). BMS-777607 has been investigated for the basic science of Malignant So...
T3113 ForetinibHOT Foretinib is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.
T3209 AMG-337 AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5nM).
T3274 S49076 S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.
T3455 Merestinib LY2801653 is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity. LY2801653 selectively ...
T3512 S49076 HCl S49076 is an effective inhibitor of MET, AXL/MER, and FGFR1/2/3. S49076 potently blocked cellular phosphorylation of MET, AXL, and FGFRs and inhibited downstrea...
T4332 c-Kit-IN-1 DCC-2618 is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).
T6057 URMC-099 URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM...
T6094 MK-2461 MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met with a mean IC50 of 2.5 nM.
T6095 JNJ-38877605 JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.
T6117 Tivantinib Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.
T6121 Tepotinib Tepotinib is an inhibitor of MET tyrosine kinase with potential antineoplastic activity.
T6128 PHA-665752 PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.
T6154 SU11274 SU11274(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.
T6260 AMG-208 AMG 208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.
T6351 Glesatinib MGCD-265-analog (structurally related to MGCD-265) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with...
T6378 AMG-458 AMG 458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.
T6517 Golvatinib Golvatinib is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor...
T6907 NPS-1034 NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.
T6982 SGI-7079 SGI-7079 is a new selective Axl inhibitor. SGI-7079 can be a dose-dependent manner inhibited growth of tumors. It is also a potential therapeutic target for EGF...
T4260 Capmatinib 2HCl INCB-28060(free base) is a novel, ATP-competitive inhibitor of c-MET kinase with an IC50 with 0.13 nM.INCB28060 exhibits picomolar enzymatic potency and is high...
T5164 Cabozantinib hydrochloride (849217-68-1(free base)) Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM).
T5414 Glumetinib Glumetinib (SCC 244) is a novel potent and selective inhibitor of c-Met kinase (IC50: 0.42 nM).
T5677 SAR125884 hydrochlorid (1116743-46-4(free base)) SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).
T5478 SRI 31215 SRI 31215, a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF act...
T5656 Norcantharidin Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
T7376 Dihexa Dihexa is an activator of the hepatocyte growth factor/c-Met (HGF/c-Met) system,it binds to HGF (Kd = 65 pM),and an analog of the peptide angiotensin IV.
TQ0210 Savolitinib Savolitinib (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).
TQ0219 MK-8033 MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).
TQ0021 Ningetinib Ningetinib (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
TQ0041 Ningetinib Tosylate Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
T3550 Ensartinib Ensartinib (X-396) is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplasti...
T4426 CEP-40783 CEP-40783 is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).
T2208 Zinc bacitracin Bacitracin Zinc is an antibiotic that interferes with the dephosphorylation of C55-isoprenyl pyrophosphate, interference for inhibition of cleavage of Tyr from ...
T7787 BMS817378 BMS817378 is a potent and selective  inhibitor of MET(IC50 : 1.7 nM).
T8399 Crizotinib hydrochloride Crizotinib hydrochloride is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)
T8416 Capmatinib hydrochloride(free base) Capmatinib hydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50 = ...
T8326 BMS-2 BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.
Crizotinib HOT
T1661CAS 877399-52-5
Crizotinib is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.
XL184
T1797CAS 1140909-48-3
Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential ...
TAE226
T1918CAS 761437-28-9
NVP-TAE226 is an effective FAK inhibitor (IC50: 5.5 nM) and most effective to Pyk2(IC50: 3.5 nM); 10- to 100-fold less effective against IGF-1R, InsR, c-Met, an...
Capmatinib
T1963CAS 1029712-80-8
Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
Altiratinib
T2054CAS 1345847-93-9
Altiratinib(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth...
RPI-1
T2282CAS 269730-03-2
RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor. 
SGX-523
T2293CAS 1022150-57-7
SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
BMS-754807
T2349CAS 1001350-96-4
Dual IGF-1R/InsR Inhibitor BMS-754807 is an oral small molecule inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine...
BMS794833
T2419CAS 1174046-72-0
BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.
Cabozantinib HOT
T2586CAS 849217-68-1
Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50s: 0.035, 1.3, 4.6, 7 and 11.3 nM).
PF-04217903
T2676CAS 956905-27-4
MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.
NVP-BVU972
T2680CAS 1185763-69-2
NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.
BMS-777607
T2699CAS 1025720-94-8
BMS-777607 is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3 (IC50: 3.9/1.1/1.8/4.3 nM). BMS-777607 has been investigated for the basic science of Malignant So...
Foretinib HOT
T3113CAS 849217-64-7
Foretinib is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.
AMG-337
T3209CAS 1173699-31-4
AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5nM).
S49076
T3274CAS 1265965-22-7
S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.
Merestinib
T3455CAS 1206799-15-6
LY2801653 is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity. LY2801653 selectively ...
S49076 HCl
T3512CAS 1265966-31-1
S49076 is an effective inhibitor of MET, AXL/MER, and FGFR1/2/3. S49076 potently blocked cellular phosphorylation of MET, AXL, and FGFRs and inhibited downstrea...
c-Kit-IN-1
T4332CAS 1225278-16-9
DCC-2618 is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).
URMC-099
T6057CAS 1229582-33-5
URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM...
MK-2461
T6094CAS 917879-39-1
MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met with a mean IC50 of 2.5 nM.
JNJ-38877605
T6095CAS 943540-75-8
JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.
Tivantinib
T6117CAS 905854-02-6
Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.
Tepotinib
T6121CAS 1100598-32-0
Tepotinib is an inhibitor of MET tyrosine kinase with potential antineoplastic activity.
PHA-665752
T6128CAS 477575-56-7
PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.
SU11274
T6154CAS 658084-23-2
SU11274(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.
AMG-208
T6260CAS 1002304-34-8
AMG 208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.
Glesatinib
T6351CAS 875337-44-3
MGCD-265-analog (structurally related to MGCD-265) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with...
AMG-458
T6378CAS 913376-83-7
AMG 458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.
Golvatinib
T6517CAS 928037-13-2
Golvatinib is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor...
NPS-1034
T6907CAS 1221713-92-3
NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.
SGI-7079
T6982CAS 1239875-86-5
SGI-7079 is a new selective Axl inhibitor. SGI-7079 can be a dose-dependent manner inhibited growth of tumors. It is also a potential therapeutic target for EGF...
Capmatinib 2HCl
T4260CAS 1197376-85-4
INCB-28060(free base) is a novel, ATP-competitive inhibitor of c-MET kinase with an IC50 with 0.13 nM.INCB28060 exhibits picomolar enzymatic potency and is high...
Cabozantinib hydrochloride (849217-68-1(free base))
T5164CAS T5164
Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM).
Glumetinib
T5414CAS 1642581-63-2
Glumetinib (SCC 244) is a novel potent and selective inhibitor of c-Met kinase (IC50: 0.42 nM).
SAR125884 hydrochlorid (1116743-46-4(free base))
T5677CAS 1116743-46-4
SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).
SRI 31215
T5478CAS 1832686-44-8
SRI 31215, a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF act...
Norcantharidin
T5656CAS 29745-04-8
Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
Dihexa
T7376CAS 1401708-83-5
Dihexa is an activator of the hepatocyte growth factor/c-Met (HGF/c-Met) system,it binds to HGF (Kd = 65 pM),and an analog of the peptide angiotensin IV.
Savolitinib
TQ0210CAS 1313725-88-0
Savolitinib (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).
MK-8033
TQ0219CAS 1001917-37-8
MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).
Ningetinib
TQ0021CAS 1394820-69-9
Ningetinib (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
Ningetinib Tosylate
TQ0041CAS 1394820-77-9
Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
Ensartinib
T3550CAS 1365267-27-1
Ensartinib (X-396) is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplasti...
CEP-40783
T4426CAS 1437321-24-8
CEP-40783 is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).
Zinc bacitracin
T2208CAS 1405-89-6
Bacitracin Zinc is an antibiotic that interferes with the dephosphorylation of C55-isoprenyl pyrophosphate, interference for inhibition of cleavage of Tyr from ...
BMS817378
T7787CAS 1174161-69-3
BMS817378 is a potent and selective  inhibitor of MET(IC50 : 1.7 nM).
Crizotinib hydrochloride
T8399CAS 1415560-69-8
Crizotinib hydrochloride is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)
Capmatinib hydrochloride(free base)
T8416CAS 1029714-89-3
Capmatinib hydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50 = ...
BMS-2
T8326CAS 888719-03-7
BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.